On June 29, 2026, Tamar Howson resigned from the Board of Directors and the Compensation Committee as she transitions into retirement. Following this, the Board appointed CEO Erik Lundgren to serve as a Class II director until the 2028 annual meeting of stockholders. Immunic, Inc. is a biotechnology company focused on developing immune-modulating therapies.
